Follow the Epi: Finding TB-Prevalent Populations to Guide TB Vaccine Protocol Design

In this plenary discussion, experts in infectious diseases discuss how real-world epidemiology data, site capacity data and biosurveillance methodology could help identify TB-prevalent populations during protocol design, helping to ensure an adequate sample for TB vaccine development.

Continue ReadingFollow the Epi: Finding TB-Prevalent Populations to Guide TB Vaccine Protocol Design

How Can We Streamline the Vaccine Development Process?

  • Post author:
  • Post category:

To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”

Continue ReadingHow Can We Streamline the Vaccine Development Process?

Building Capacity for Tuberculosis Research in China: The China TB Clinical Trials Consortium (CTCTC)

  • Post author:
  • Post category:

To help address the high global TB incidence and related death rate, the China TB Clinical Trials Consortium (CTCTC) was established by government and industry partners to help build clinical research capacity in China, which has a particularly high tuberculosis incidence.

Continue ReadingBuilding Capacity for Tuberculosis Research in China: The China TB Clinical Trials Consortium (CTCTC)

About FHI Clinical

  • Post author:
  • Post category:

FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.

Continue ReadingAbout FHI Clinical